Evidence map›Paper›PMID 24855945›Full record

ArticleCell2014

Deconstructing the peptide-MHC specificity of T cell recognition.

Michael E Birnbaum, Juan L Mendoza, Dhruv K Sethi, Shen Dong, Jacob Glanville, Jessica Dobbins, Engin Ozkan, Mark M Davis, Kai W Wucherpfennig, K Christopher Garcia

Open access · bronzeAbstract read
In one paragraph

Article in Cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 352 papers.

0numbers the graph read from it
0cells of the map it votes in
352citing papers in PubMed
20.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

352 citing papers in PubMed, 563 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Unbiased avidity-based isolation of antigen-specific T cells.Journal for immunotherapy of cancer · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

292 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Michael E BirnbaumDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA; Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Juan L MendozaDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dhruv K SethiDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Shen DongDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jacob GlanvilleDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jessica DobbinsDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
Engin OzkanDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA; The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Mark M DavisDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Kai W WucherpfennigDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Program in Immunology, Harvard Medical School, Boston, MA 02115, USA.
K Christopher GarciaDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA; Program in Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: kcgarcia@stanford.edu.
Stanford University · USHarvard University · USHoward Hughes Medical Institute · USDana-Farber Cancer Institute · US

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
TCR recognition of MHC class II peptide compexes in multiple sclerosisP01AI045757 · NIAID · DANA-FARBER CANCER INSTITUTE · PI KUCHROO, VIJAY K., LOVE, JOHN CHRISTOPHER · 1999 to 2017
$22.8M
Structural correlates of T cell receptor signalingR01AI103867 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2014 to 2026
$5.3M
Impact of MHC Genotype on Ex Vivo T cell Function in Type 1 DiabetesDP3DK097681 · NIDDK · DANA-FARBER CANCER INST · PI LOVE, JOHN CHRISTOPHER, WUCHERPFENNIG, KAI W · 2012 to 2012
$3.9M
T CELL RECEPTOR STRUCTURE AND EXPRESSIONR01AI022511 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 1985 to 2014
$3.3M
Molecular Principles of TCR Recognition and Activation by peptide-MHCR01AI048540 · NIAID · STANFORD UNIVERSITY · PI GARCIA, KENAN CHRISTOPHER · 2001 to 2010
$2.9M
Diversifying interferon functions through combinatorial and structural biologyK01CA175127 · NCI · STANFORD UNIVERSITY · PI MENDOZA, JUAN LUIS · 2013 to 2017
$584k
Howard Hughes Medical InstituteNCI NIH HHS K01 CA175127NIAID NIH HHS P01 AI045757NIAID NIH HHS R01 AI022511NIAID NIH HHS R01 AI03867NIAID NIH HHS R01 AI048540NIAID NIH HHS R01 AI103867NIAID NIH HHS U19 AI057229NIDDK NIH HHS DP3 DK097681PHS HHS U19 4100041120
6 · The paper itself

Abstract

In order to survey a universe of major histocompatibility complex (MHC)-presented peptide antigens whose numbers greatly exceed the diversity of the T cell repertoire, T cell receptors (TCRs) are thought to be cross-reactive. However, the nature and extent of TCR cross-reactivity has not been conclusively measured experimentally. We developed a system to identify MHC-presented peptide ligands by combining TCR selection of highly diverse yeast-displayed peptide-MHC libraries with deep sequencing. Although we identified hundreds of peptides reactive with each of five different mouse and human TCRs, the selected peptides possessed TCR recognition motifs that bore a close resemblance to their known antigens. This structural conservation of the TCR interaction surface allowed us to exploit deep-sequencing information to computationally identify activating microbial and self-ligands for human autoimmune TCRs. The mechanistic basis of TCR cross-reactivity described here enables effective surveillance of diverse self and foreign antigens without necessitating degenerate recognition of nonhomologous peptides.

Indexed as

AlgorithmsAmino Acid SequenceAnimalsCross ReactionsHigh-Throughput Nucleotide SequencingHLA AntigensHumansLigandsMiceModels, MolecularPeptide LibraryPeptidesReceptors, Antigen, T-CellT-LymphocytesHLA AntigensLigandsPeptide LibraryPeptidesReceptors, Antigen, T-Cell

Identifiers

PMID24855945
PMCPMC4071348
OpenAlexW1979731533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.